| Product Code: ETC6919186 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
In 2024, the Czech Republic`s import trend for large molecule drug substance CDMO market experienced a significant decline, with a growth rate of -85.89% compared to the previous year. However, the compound annual growth rate (CAGR) for 2020-2024 stood at a positive 8.06%. This sharp decline in import momentum from 2023-2024 may be attributed to shifts in demand dynamics or changes in trade policies affecting market stability.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Czech Republic Large Molecule Drug Substance CDMO Market Overview |
3.1 Czech Republic Country Macro Economic Indicators |
3.2 Czech Republic Large Molecule Drug Substance CDMO Market Revenues & Volume, 2021 & 2031F |
3.3 Czech Republic Large Molecule Drug Substance CDMO Market - Industry Life Cycle |
3.4 Czech Republic Large Molecule Drug Substance CDMO Market - Porter's Five Forces |
3.5 Czech Republic Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By Service, 2021 & 2031F |
3.6 Czech Republic Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By Source, 2021 & 2031F |
3.7 Czech Republic Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By End-user, 2021 & 2031F |
4 Czech Republic Large Molecule Drug Substance CDMO Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing demand for biologics and large molecule drugs in the pharmaceutical industry |
4.2.2 Growing trend of outsourcing drug substance manufacturing to Contract Development and Manufacturing Organizations (CDMOs) |
4.2.3 Technological advancements in the production of large molecule drug substances |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements and compliance standards in the pharmaceutical industry |
4.3.2 High initial investments and operational costs associated with setting up large molecule drug substance manufacturing facilities |
4.3.3 Intense competition among CDMOs offering similar services |
5 Czech Republic Large Molecule Drug Substance CDMO Market Trends |
6 Czech Republic Large Molecule Drug Substance CDMO Market, By Types |
6.1 Czech Republic Large Molecule Drug Substance CDMO Market, By Service |
6.1.1 Overview and Analysis |
6.1.2 Czech Republic Large Molecule Drug Substance CDMO Market Revenues & Volume, By Service, 2021- 2031F |
6.1.3 Czech Republic Large Molecule Drug Substance CDMO Market Revenues & Volume, By Contract Manufacturing, 2021- 2031F |
6.1.4 Czech Republic Large Molecule Drug Substance CDMO Market Revenues & Volume, By Clinical, 2021- 2031F |
6.1.5 Czech Republic Large Molecule Drug Substance CDMO Market Revenues & Volume, By Commercial, 2021- 2031F |
6.1.6 Czech Republic Large Molecule Drug Substance CDMO Market Revenues & Volume, By Contract Development, 2021- 2031F |
6.1.7 Czech Republic Large Molecule Drug Substance CDMO Market Revenues & Volume, By Cell Line Development, 2021- 2031F |
6.1.8 Czech Republic Large Molecule Drug Substance CDMO Market Revenues & Volume, By Process Development, 2021- 2031F |
6.2 Czech Republic Large Molecule Drug Substance CDMO Market, By Source |
6.2.1 Overview and Analysis |
6.2.2 Czech Republic Large Molecule Drug Substance CDMO Market Revenues & Volume, By Mammalian, 2021- 2031F |
6.2.3 Czech Republic Large Molecule Drug Substance CDMO Market Revenues & Volume, By Microbial, 2021- 2031F |
6.2.4 Czech Republic Large Molecule Drug Substance CDMO Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Czech Republic Large Molecule Drug Substance CDMO Market, By End-user |
6.3.1 Overview and Analysis |
6.3.2 Czech Republic Large Molecule Drug Substance CDMO Market Revenues & Volume, By Biotech Companies, 2021- 2031F |
6.3.3 Czech Republic Large Molecule Drug Substance CDMO Market Revenues & Volume, By CRO, 2021- 2031F |
6.3.4 Czech Republic Large Molecule Drug Substance CDMO Market Revenues & Volume, By Others, 2021- 2031F |
7 Czech Republic Large Molecule Drug Substance CDMO Market Import-Export Trade Statistics |
7.1 Czech Republic Large Molecule Drug Substance CDMO Market Export to Major Countries |
7.2 Czech Republic Large Molecule Drug Substance CDMO Market Imports from Major Countries |
8 Czech Republic Large Molecule Drug Substance CDMO Market Key Performance Indicators |
8.1 Percentage of capacity utilization at large molecule drug substance manufacturing facilities |
8.2 Number of new partnerships and collaborations between CDMOs and pharmaceutical companies |
8.3 Average turnaround time for large molecule drug substance manufacturing orders |
8.4 Rate of successful regulatory approvals for large molecule drug substances manufactured by CDMOs |
8.5 Number of patents filed for innovative large molecule drug substance manufacturing processes |
9 Czech Republic Large Molecule Drug Substance CDMO Market - Opportunity Assessment |
9.1 Czech Republic Large Molecule Drug Substance CDMO Market Opportunity Assessment, By Service, 2021 & 2031F |
9.2 Czech Republic Large Molecule Drug Substance CDMO Market Opportunity Assessment, By Source, 2021 & 2031F |
9.3 Czech Republic Large Molecule Drug Substance CDMO Market Opportunity Assessment, By End-user, 2021 & 2031F |
10 Czech Republic Large Molecule Drug Substance CDMO Market - Competitive Landscape |
10.1 Czech Republic Large Molecule Drug Substance CDMO Market Revenue Share, By Companies, 2024 |
10.2 Czech Republic Large Molecule Drug Substance CDMO Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |